<em>One of effective and safe immunomodulators for prophylaxis and treatment of frequently ailing children is pidotimod (Imunorix). Efficacy of the drug in pediatric practice was studied in more than 3200 patients with acute and recurrent respiratory infections. The article shows reasonability of pidotimod administration in children with acute and chronic bronchitis. This fact was confirmed with doubleblinded placebo-controlled studies. Treatment with pidotimod results in decreased terms of recovery of chronic bronchitis exacerbation, shortening of exacerbation. Realization of stable effect is related to recovery of key functions of inborn and adaptive immunity, it begins in 15 days after intake of the drug in therapeutic dose. Prophylactic...
In this article authors consider frequent development of respiratory infections in children, which i...
The therapeutic activity and safety of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazo...
Despite the use of antibiotics and vaccines, the frequency of respiratory tract infections is still ...
<p><em>The data on pidotimod (Imunorix) effectiveness in prophylaxis of bronchial asthma exacerbatio...
<em>The article contains analysis of results of international trial of pidotimod (imunorix) efficien...
<p><em>The article describes actual pediatric problem — frequent development of respiratory infectio...
<em>This trial studied effectiveness and safety of pidotimoid (Imunorix) in complex treatment of chi...
<em>The immunomodulating activity of pidotimod (imunorix) was evaluated in a doublebblind, placebobc...
<em>Infections of airways are one of significant causes of morbidity in children. Approximately 70% ...
AIM: Recurrent respiratory infections (RRI) constitute a social problem for both the pharmaco-econom...
AIM: Recurrent respiratory infections (RRI) constitute a social problem for both the pharmaco-econom...
<em>Viruses are the leading etiological factor of recurrent infections of respiratory tract. Experim...
<em>This article presents results of clinical observation, carried out for the purpose of evaluation...
Acute respiratory tract infections (ARTIs) are very common in pediatric age and reach a peak in the ...
In this article authors consider frequent development of respiratory infections in children, which i...
In this article authors consider frequent development of respiratory infections in children, which i...
The therapeutic activity and safety of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazo...
Despite the use of antibiotics and vaccines, the frequency of respiratory tract infections is still ...
<p><em>The data on pidotimod (Imunorix) effectiveness in prophylaxis of bronchial asthma exacerbatio...
<em>The article contains analysis of results of international trial of pidotimod (imunorix) efficien...
<p><em>The article describes actual pediatric problem — frequent development of respiratory infectio...
<em>This trial studied effectiveness and safety of pidotimoid (Imunorix) in complex treatment of chi...
<em>The immunomodulating activity of pidotimod (imunorix) was evaluated in a doublebblind, placebobc...
<em>Infections of airways are one of significant causes of morbidity in children. Approximately 70% ...
AIM: Recurrent respiratory infections (RRI) constitute a social problem for both the pharmaco-econom...
AIM: Recurrent respiratory infections (RRI) constitute a social problem for both the pharmaco-econom...
<em>Viruses are the leading etiological factor of recurrent infections of respiratory tract. Experim...
<em>This article presents results of clinical observation, carried out for the purpose of evaluation...
Acute respiratory tract infections (ARTIs) are very common in pediatric age and reach a peak in the ...
In this article authors consider frequent development of respiratory infections in children, which i...
In this article authors consider frequent development of respiratory infections in children, which i...
The therapeutic activity and safety of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazo...
Despite the use of antibiotics and vaccines, the frequency of respiratory tract infections is still ...